Drug
Capivasertib
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Hyperglycaemia | 295 | 63.4 | 71.0 | signal |
| 2 | Erythema Multiforme | 68 | 56.9 | 58.3 | signal |
| 3 | Diabetic Ketoacidosis | 84 | 27.2 | 28.1 | signal |
| 4 | Metastases To Liver | 51 | 22.6 | 23.0 | signal |
| 5 | Metastases To Bone | 34 | 16.1 | 16.3 | signal |
| 6 | Metastases To Central Nervous System | 19 | 11.5 | 11.6 | signal |
| 7 | Malignant Neoplasm Progression | 146 | 11.1 | 11.7 | signal |
| 8 | Metastases To Lung | 16 | 10.7 | 10.8 | signal |
| 9 | Drug Eruption | 22 | 9.7 | 9.7 | signal |
| 10 | Blood Glucose Fluctuation | 12 | 8.5 | 8.5 | signal |
| 11 | Blood Glucose Abnormal | 19 | 8.0 | 8.0 | signal |
| 12 | Liver Function Test Increased | 21 | 7.6 | 7.7 | signal |
| 13 | Disease Progression | 115 | 7.6 | 7.8 | signal |
| 14 | Ascites | 26 | 6.8 | 6.9 | signal |
| 15 | Rash | 376 | 6.7 | 7.6 | signal |
| 16 | Rash Maculo-papular | 18 | 6.3 | 6.3 | signal |
| 17 | Diabetes Mellitus | 62 | 6.3 | 6.4 | signal |
| 18 | Stevens-johnson Syndrome | 16 | 5.6 | 5.6 | signal |
| 19 | Stomatitis | 41 | 5.2 | 5.3 | signal |
| 20 | Diarrhoea | 420 | 5.1 | 5.8 | signal |
| 21 | Breast Cancer Metastatic | 7 | 5.1 | 5.1 | signal |
| 22 | Blood Sodium Decreased | 12 | 4.9 | 5.0 | signal |
| 23 | Therapy Change | 6 | 4.8 | 4.8 | signal |
| 24 | Electrolyte Imbalance | 7 | 4.7 | 4.7 | signal |
| 25 | Hepatomegaly | 6 | 4.7 | 4.7 | signal |
| 26 | Blood Glucose Increased | 114 | 4.7 | 4.8 | signal |
| 27 | Pneumonitis | 16 | 4.6 | 4.6 | signal |
| 28 | Ovarian Cancer | 5 | 4.2 | 4.2 | signal |
| 29 | Hypoglycaemia | 25 | 4.0 | 4.0 | signal |
| 30 | Skin Reaction | 7 | 3.9 | 3.9 | signal |
| 31 | Death | 411 | 3.7 | 4.2 | signal |
| 32 | Eating Disorder | 10 | 3.6 | 3.6 | signal |
| 33 | Decreased Activity | 5 | 3.6 | 3.6 | signal |
| 34 | Hepatic Function Abnormal | 17 | 3.6 | 3.6 | signal |
| 35 | Pulmonary Thrombosis | 5 | 3.5 | 3.6 | signal |
| 36 | Skin Disorder | 15 | 3.5 | 3.5 | signal |
| 37 | Interstitial Lung Disease | 20 | 3.2 | 3.2 | signal |
| 38 | Hepatotoxicity | 9 | 3.1 | 3.2 | signal |
| 39 | Glycosylated Haemoglobin Increased | 10 | 3.1 | 3.1 | signal |
| 40 | Thirst | 7 | 3.0 | 3.0 | signal |
| 41 | Neoplasm Malignant | 24 | 2.8 | 2.8 | signal |
| 42 | Spinal Fracture | 7 | 2.7 | 2.7 | signal |
| 43 | Insurance Issue | 5 | 2.6 | 2.6 | no signal |
| 44 | Hepatic Cancer | 8 | 2.6 | 2.6 | signal |
| 45 | Blood Glucose Decreased | 14 | 2.2 | 2.3 | signal |
| 46 | Central Nervous System Lesion | 4 | 2.2 | 2.2 | no signal |
| 47 | Diabetes Mellitus Inadequate Control | 5 | 2.2 | 2.2 | no signal |
| 48 | Nephropathy Toxic | 3 | 2.1 | 2.1 | no signal |
| 49 | Product Dose Omission In Error | 7 | 2.0 | 2.0 | no signal |
| 50 | Palmar-plantar Erythrodysaesthesia Syndrome | 4 | 1.3 | 1.3 | no signal |
| 51 | Breast Cancer | 11 | 0.9 | 0.9 | no signal |